Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

siRNA Therapeutics Market: GalNAc-Conjugated Liver-Directed Demand, Subcutaneous Administration Shift Growth, and Cardiometabolic Indication Expansion Adoption to Drive Strong Market Expansion Through 2036

The global siRNA Therapeutics Market was valued at USD 3,245.8 million in 2025 and is projected to expand at a strong CAGR of 18.0%, reaching approximately USD 16,988.0 million by 2036. This growth trajectory is being driven by sustained commercial demand for GalNAc-conjugated liver-directed siRNA therapeutics, growing shift toward subcutaneous administration relative to earlier intravenous LNP-based products, and continued indication expansion across cardiometabolic, oncology, and central nervous system applications. The market comprises multiple approved GalNAc-siRNA products addressing hereditary transthyretin amyloidosis, primary hyperoxaluria, acute hepatic porphyria, and hypercholesterolemia, alongside a substantial clinical-stage pipeline extending into extrahepatic applications.

The market’s strong 18.0% CAGR reflects siRNA technology’s continued maturation from patisiran’s original lipid-nanoparticle delivery breakthrough into a substantially GalNAc-dominated commercial landscape, generating structured demand from hospitals and specialty treatment centers well above discretionary specialty pharmaceutical demand growth. GalNAc has become particularly important for liver-directed siRNA therapies and represents a leading delivery technology, with current clinical development continuing to expand beyond liver targeting into cardiovascular, oncology, central nervous system, and infectious disease applications. Metabolic disorders continue to represent a major revenue segment, while oncology is expected to be among the faster-growing therapeutic areas as the technology extends into non-hepatic applications. Coverage extending across multiple siRNA chemistries, delivery technologies, and therapeutic areas underscores the breadth of clinical and manufacturing infrastructure now supporting this well-established and continuously diversifying category.

Executive Snapshot

How does GalNAc-conjugated liver-directed demand drive the siRNA therapeutics market?
Hospitals and specialty treatment centers continue to administer GalNAc-conjugated siRNA products for hereditary transthyretin amyloidosis, primary hyperoxaluria, acute hepatic porphyria, and hypercholesterolemia, establishing this delivery technology as the leading platform for the category. As GalNAc conjugation continues to anchor the majority of current commercial siRNA products, procurement associated with this delivery platform is expected to remain the dominant category through the forecast period.

What role does subcutaneous administration shift growth play in market expansion?
Treatment centers continue to shift toward subcutaneous administration for GalNAc-conjugated products, sustaining structured demand from developers pursuing this convenience-driven administration route relative to the intravenous infusion required for LNP-based products such as patisiran.

How does cardiometabolic indication expansion adoption sustain market growth?
Biopharmaceutical developers continue to advance siRNA candidates targeting cardiovascular risk reduction, dyslipidemia, and hypertriglyceridemia, sustaining structured demand from developers pursuing this substantial therapeutic area given metabolic disorders’ status as a major current revenue segment for the category.

What is driving demand for siRNA therapeutics in oncology applications?
Developers pursuing siRNA candidates for solid tumors and hematological malignancies continue to extend RNA interference technology beyond its historical hepatic and rare disease core, generating incremental demand among clinical-stage biopharmaceutical developers pursuing this therapeutic area expected to be among the faster-growing segments.

How does extrahepatic delivery technology demand sustain the market?
Biopharmaceutical developers continue to advance polymer-based, viral vector-based, and exosome-based delivery technologies designed to extend siRNA therapeutic reach beyond conventional liver targeting, sustaining structured demand from developers pursuing these differentiated platforms for central nervous system, ophthalmic, and other extrahepatic applications.

Which siRNA therapeutics market segments are growing fastest?
The fastest-growing segments include oncology applications, extrahepatic delivery technology extending beyond GalNAc-conjugated hepatic targeting, subcutaneous administration formats, and central nervous system and neurological disease indications.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: siRNA Therapeutics Market

  • GalNAc-siRNA conjugates sustaining the leading share of current commercial delivery technology activity: This delivery platform continues to anchor the substantial majority of current siRNA therapeutics commercial revenue given its established role in liver-directed applications.
  • Metabolic disorders sustaining a leading share of current therapeutic area demand: Hypercholesterolemia, dyslipidemia, and related cardiometabolic indications continue to represent a major revenue segment for the category.
  • Subcutaneous administration sustaining structured demand growth above intravenous delivery for GalNAc-conjugated products: This convenience-driven shift continues to differentiate newer commercial products from earlier LNP-based intravenous therapies.
  • Rare genetic diseases sustaining an established indication category alongside expanding cardiometabolic and oncology applications: Hereditary transthyretin amyloidosis and related conditions continue to anchor substantial commercial activity as the category diversifies.
  • Oncology applications sustaining structured demand growth as an increasingly important therapeutic area: This category continues to be expected among the faster-growing segments as siRNA technology extends beyond hepatic targeting.
  • Lipid nanoparticle delivery sustaining a validated complementary platform alongside dominant GalNAc conjugation technology: This delivery approach, central to patisiran’s original commercial breakthrough, continues to represent an important technology alongside conjugate-based approaches.

Market Segmentation: siRNA Therapeutics Market

By siRNA Type
  • Synthetic siRNA
  • Chemically Modified siRNA
  • Unmodified siRNA
  • Dicer-Substrate siRNA (DsiRNA)
  • Other Engineered siRNA
By Delivery Technology
  • Conjugate-Based Delivery
  • Lipid-Based Deliver
  • Polymer-Based Delivery
  • Viral Vector-Based Delivery
  • Exosome-Based Delivery
  • Other Delivery Technologies
By Indication
  • Cardiometabolic
  • Rare/Genetic
  • Infectious
  • Oncology
  • Neurological
  • Others
By Route of Administration
  • Intravenous
  • Subcutaneous
  • Intrathecal
  • Intramuscular
  • Intranasal
  • Intravitreal
  • Intradermal
  • Other Routes
By Therapeutic Area
  • Metabolic Disorders
  • Cardiovascular Diseases
  • Rare Genetic Diseases
  • Oncology
  • Neurological Disorders
  • Hematological Disorders
  • Infectious Diseases
  • Ophthalmic Disorders
  • Respiratory Diseases
  • Other Therapeutic Areas
By Therapeutic Objective
  • Disease-Causing Protein Suppression
  • Pathogenic Gene Silencing
  • Metabolic Pathway Modulation
  • Oncogene Silencing
  • Viral Gene Silencing
  • Protein Expression Reduction
  • Other Gene-Silencing Objectives
By Product Development Stage
  • Commercially Available Products
  • Phase III Products
  • Phase II Products
  • Phase I Products
  • Preclinical Products
By End User
  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Clinics
  • Academic & Research Institutes
  • Contract Research Organizations (CROs)
  • Contract Development & Manufacturing Organizations (CDMOs)
  • Specialty Clinics
  • Other End Users
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: siRNA Therapeutics Market

  1. Sustained commercial performance of GalNAc-conjugated products driving continued liver-directed therapeutic investment: This established delivery platform continues to support structured demand above the discretionary specialty pharmaceutical baseline.
  2. Growing patient and clinician preference for subcutaneous administration supporting improved treatment convenience: This administration route continues to attract structured developer investment pursuing improved patient adherence relative to intravenous infusion.
  3. Continued extension into cardiometabolic disease broadening the addressable therapeutic market: This diversification continues to substantially broaden the category’s overall addressable commercial opportunity beyond rare genetic disease.
  4. Sustained developer investment in oncology applications supporting pipeline diversification into faster-growing therapeutic areas: This therapeutic area continues to generate incremental developer interest in extending RNA interference technology beyond hepatic targeting.
  5. Growing research investment in extrahepatic delivery technology supporting expanded tissue-targeting capability: Polymer-based and exosome-based systems continue to attract structured developer investment pursuing broader therapeutic applicability.
  6. Maturing regulatory pathways supporting continued approval momentum across multiple siRNA therapeutic indications: Accumulating global regulatory experience continues to support faster and more predictable approval pathways for new siRNA-based candidates.

Regional Outlook: siRNA Therapeutics Market

  • North America: The United States accounts for the largest share of global demand, supported by extensive specialty treatment center infrastructure and the largest concentration of approved siRNA therapeutic products globally.
  • Europe: Germany, the United Kingdom, and France anchor regional demand, supported by growing specialized treatment center capacity and an established European regulatory pathway.
  • Asia-Pacific: China, Japan, and South Korea represent some of the fastest-growing regional markets as regional biopharmaceutical developers expand siRNA therapeutic manufacturing and clinical development capacity.
  • Latin America: Brazil and Mexico represent an emerging regional demand base as specialized treatment centers begin to expand siRNA therapeutic access.

Competitive Landscape: siRNA Therapeutics Market

Key Players
Alnylam Pharmaceuticals, Inc., Novartis AG, Arrowhead Pharmaceuticals, Inc., Silence Therapeutics plc, Amgen Inc., Regeneron Pharmaceuticals, Inc., AstraZeneca plc, Dicerna Pharmaceuticals (Novo Nordisk A/S), Sanofi S.A., Genevant Sciences Corporation, Sirnaomics, Inc., Hengrui Pharmaceuticals Co., Ltd., Alnylam Pharmaceuticals (Vutrisiran/Onpattro Portfolio), Quark Pharmaceuticals, Inc.

  • Alnylam Pharmaceuticals, Inc. [March 2026] — confirmed continued commercial growth of its GalNAc-conjugated siRNA portfolio, with the company noting sustained demand across hereditary transthyretin amyloidosis and primary hyperoxaluria treatment accounts.
  • Novartis AG [December 2025] — reported continued commercial expansion of its PCSK9-targeted siRNA product for cardiovascular risk reduction, with the company noting sustained physician adoption of extended-dosing-interval lipid management.
  • Arrowhead Pharmaceuticals, Inc. [September 2025] — confirmed continued clinical development of its extrahepatic delivery platform, with the company reporting structured investor interest in expanding siRNA-based gene silencing beyond liver-directed applications.

Consultant POV

The siRNA Therapeutics Market’s strong 18.0% CAGR from USD 3,245.8 million in 2025 toward approximately USD 16,988.0 million by 2036 is anchored in sustained GalNAc-conjugated liver-directed demand, growing subcutaneous administration shift activity, and continued cardiometabolic indication expansion adoption. Sustained clinical and manufacturing investment from companies including Alnylam Pharmaceuticals, Inc., Novartis AG, and Arrowhead Pharmaceuticals, Inc. confirms the siRNA Therapeutics Market will sustain strong growth through 2036.

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report